Welcome to our dedicated page for Alzamend Neuro news (Ticker: ALZN), a resource for investors and traders seeking the latest updates and insights on Alzamend Neuro stock.
Alzamend Neuro, Inc. reports clinical-stage biopharmaceutical developments for therapies aimed at Alzheimer's disease, bipolar disorder, major depressive disorder and post-traumatic stress disorder. Its pipeline centers on AL001, a patented ionic cocrystal formulation that delivers lithium with salicylate and L-proline, and ALZN002, a cell-based therapeutic vaccine approach designed to target Alzheimer's beta-amyloid.
Recurring news includes Phase II “Lithium in Brain” clinical study updates, brain and blood lithium pharmacokinetic and pharmacodynamic data, research activity with Massachusetts General Hospital, scientific presentations, annual financial results and financing actions supporting the company's clinical programs.
Alzamend Neuro has priced its initial public offering (IPO) of 2,500,000 shares at $5.00 each, aiming to raise gross proceeds of $12.5 million. The IPO is expected to commence trading on Nasdaq under the ticker symbol ALZN on June 15, 2021, with an anticipated closing date of June 17, 2021. Underwriters have a 45-day option to purchase an additional 375,000 shares. Alzamend focuses on developing treatments for neurodegenerative diseases and psychiatric disorders, particularly Alzheimer’s Disease, with two novel product candidates licensed from the University of South Florida.